Bone
Volume 33, Issue 4 , Pages 589-596 , October 2003

The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status

  • Jan J Stepan

      Affiliations

    • Charles University School of Medicine, Prague, Czech Republic
    • Corresponding Author InformationCorresponding author. 3rd Department of Internal Medicine, Charles University Faculty of Medicine, U nemocnice 1, 128 00 Prague, Czech Republic.
    • ,
  • Peter Burckhardt

      Affiliations

    • Départment de Médecine Interne, University of Lausanne, Lausanne, Switzerland
    • ,
  • Václav Hána

      Affiliations

    • Charles University School of Medicine, Prague, Czech Republic

Received 10 March 2003 ,Revised 26 May 2003 ,Accepted 2 June 2003.

References 

  1. Jackson JA, Kleerekoper M. Osteoporosis in men (diagnosis, pathophysiology, and prevention). Med Baltimore. 1990;69:137–152
  2. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141
  3. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women (cross sectional analysis). Br Med J. 1997;315:221–225
  4. Kaufman JM, Compston J, Audran MA, Avouac B, Devogelaer JP, Lemmel EM, et al. Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis. Calcif Tissue Int. 1999;65:4–7
  5. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, et al. Management of male osteoporosis (report of the UK Consensus Group). Q J Med. 1998;91:71–92
  6. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604–610
  7. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997;103:298–307
  8. Thiebaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int. 1994;4:76–83
  9. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int. 1998;8:97–103
  10. Monier Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs (effects on bone morphometry and mineral properties). J Bone Miner Res. 1999;14:1768–1778
  11. Monier Faugere MC, Friedler RM, Bauss F, Malluche HH. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 1993;8:1345–1355
  12. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate (a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study). Bone. 1996;19:527–533
  13. Barrett Connor EI, Von Muhlen DG, Kritz Silverstein D. Bioavailable testosterone and depressed mood in older men (the Rancho Bernardo Study). J Clin Endocrinol Metab. 1999;84:573–577
  14. Rovet J, Netley C, Keenan M, Bailey J, Stewart D. The psychoeducational profile of boys with Klinefelter syndrome. J Learn Disabil. 1996;29:180–196
  15. Schmid W, Widmer O. [School and occupational history of 30 patients with Klinefelter's syndrome. Significance of early diagnosis]. Schweiz Med Wochenschr. 1983;113:1790–1794
  16. McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly (means to defining hypovitaminosis D). Osteoporos Int. 1998;8(Suppl 2):S3–6
  17. Burckhardt P, Havelka S, Lips P, Meunier PJ, Peterlik M, Scharla S, et al. Konsensuskonferenz uber die optimale Kalzium- and Vitamin D-Zufuhr. J Miner Stoffwechs. 1995;2:5–11
  18. Dubovsky J, Hrba J, Pacovsky V. Acute effects of calcium infusion on hydroxyproline. Clin Chim Acta. 1967;17:107–110
  19. Klinefelter HFJ, Reifenstein ECJ, Albright F. Syndrome characterized by gynecomastia, aspermatogenesis without a-leydigism, and increased excretion of folicle-stimulating hormone. J Clin Endocrinol. 1942;2:615–627
  20. Horowitz M, Nordin BEC, Aaron JE, Steurer T, Francis RM, Philcox JC, et al. Osteoporosis and Klinefelter's syndrome. In:  Bandmann J,  Breit S editor. Klinefelter's syndrome. Berlin: Springer–Verlag; 1984;p. 51–61
  21. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss (effect of calcitonin treatment on biochemical indices of bone remodeling). J Clin Endocrinol Metab. 1989;69:523–527
  22. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555–3561
  23. Stepan JJ, Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta. 1999;288:121–135
  24. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687–694
  25. Tonino RP, Meunier PJ, Emkey R, Rodriguez Portales JA, Menkes CJ, Wasnich RD, et al. Skeletal benefits of alendronate (7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group). J Clin Endocrinol Metab. 2000;85:3109–3115
  26. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833–1837
  27. Garnero P, Cloos P, Sornay Rendu E, Qvist P, Delmas PD. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women (The OFELY prospective study). J Bone Miner Res. 2002;17:826–833
  28. Traba ML, Calero JA, Mendez Davila C, Garcia Moreno C, de la Piedra C. Different behaviors of serum and urinary CrossLaps ELISA in the assessment of bone resorption in healthy girls. Clin Chem. 1999;45:682–683

PII: S8756-3282(03)00205-9

doi: 10.1016/S8756-3282(03)00205-9

Bone
Volume 33, Issue 4 , Pages 589-596 , October 2003

Article Tools

* Image Usage & Resolution